PreTarg-it®: A Mechanism-Guided Pretargeting Strategy to Maximize Tumor Targeting, Improve Therapeutic Windows, and Overcome Resistance Mechanisms
- Bringing together the strengths of two worlds: antibody-driven tumor specificity and accumulation with the rapid systemic clearance of small molecules for selective tumor irradiation.
- Targeting tumor-specific antigens oxMIF and HER2 with pharmacokinetically optimized antibodies to ensure persistent tumor irradiation while sparing healthy tissue
- Offering a mechanism-guided strategy to maximize therapeutic efficacy and addressing tumor resistance mechanisms